NCNA
NuCana PLC
NASDAQ: NCNA · HEALTHCARE · BIOTECHNOLOGY
$1.05
+0.00% today
Updated 2026-10-14
Market cap
$4.58M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$0.00
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-10.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →275 stocks currently score above 75
Price targets
Analyst target
$104.00
+9804.76%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.03x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -10.61 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-1.96M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-32.02M | $-27.63M | $-19.00M | $-29.35M | $-3.10M |
| EPS | — | — | — | — | $0.00 |
| Free cash flow | $-23.68M | $-26.92M | $-19.41M | $-7.66M | $-1.96M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
NuCana PLC trades at $1.05. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -10.61, it sits in the distress.
Frequently asked questions
What is NuCana PLC's stock price?
NuCana PLC (NCNA) trades at $1.05.
Is NuCana PLC overvalued?
NuCana PLC carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of NuCana PLC (NCNA)?
The 12-month analyst consensus target is $104.00, about 9804.8% above the current $1.05. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
NuCana PLC's Altman Z-Score is -10.61, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-137.68%
Beta2.31
50D MA$1.37
200D MA$1.94
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—